No Data
Applied Therapeutics Receives Complete Response Letter From U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow. -- Barrons.com
RBC Capital Downgrades Applied Therapeutics to Sector Perform, Lowers Price Target to $4
Applied Therapeutics Analyst Ratings
Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug
Applied Therapeutics Price Target Lowered to $5 From $14 at Baird